(Q38219290)

31 August 2017

title

Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories (English)

1 reference

31 August 2017

1 reference

1 reference

Lei Cheng

1

1 reference

31 August 2017

Wei Ren

2

1 reference

31 August 2017

Li Xie

3

1 reference

31 August 2017

Ming Li

4

1 reference

31 August 2017

Jiang Liu

5

1 reference

31 August 2017

Jing Hu

6

1 reference

31 August 2017

Bao-Rui Liu

7

1 reference

31 August 2017

Xiao-Ping Qian

8

1 reference

31 August 2017

language of work or name

1 reference

11 June 2014

1 reference

Cancer Chemotherapy and Pharmacology

31 August 2017

published in

1 reference

31 August 2017

volume

74

1 reference

31 August 2017

issue

1

1 reference

31 August 2017

page(s)

1-13

1 reference

31 August 2017

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Phosphorylated insulin-like growth factor 1 receptor is implicated in resistance to the cytostatic effect of gefitinib in colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Tumour heterogeneity and drug resistance: personalising cancer medicine through functional genomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Tumor heterogeneity revealed by KRAS, BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor mutation profile differences and their therapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Colorectal carcinomas, KRAS p.G13D mutant allele-specific imbalance, and anti-epidermal growth factor receptor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Mutant allele-specific imbalance modulates prognostic impact of KRAS mutations in colorectal adenocarcinoma and is associated with worse overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Ras oncogenes: split personalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Genomic and biological characterization of exon 4 KRAS mutations in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Study of critical role of c-Met and its inhibitor SU11274 in colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

The biology and clinical relevance of the PTEN tumor suppressor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Loss of PTEN expression as a predictor of resistance to anti-EGFR monoclonal therapy in metastatic colorectal cancer: evidence from retrospective studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

The role of insulin-like growth factor 1 and its receptor in the formation and development of colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

The insulin-like growth factor type 1 receptor and colorectal neoplasia: insights into invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway--therapeutic perspectives in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type KRAS mCRC Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Activated but not resting regulatory T cells accumulated in tumor microenvironment and correlated with tumor progression in patients with colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Immune microenvironmental shift along human colorectal adenoma-carcinoma sequence: is it relevant to tumor development, biomarkers and biotherapeutic targets?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2489-6

10.1007/S00280-014-2489-6

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

31 August 2017

1019597319

0 references

1 reference